A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

524

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Triple Negative Breast Cancer

Interventions

DRUG

SKB264

IV Infusion

DRUG

Paclitaxel

IV Infusion.

DRUG

Nab-paclitaxel

IV infusion.

DRUG

Capecitabine

Tablet. Oral route of administration.

DRUG

Eribulin

IV infusion.

DRUG

Carboplatin

IV infusion.

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

INDUSTRY